Genomic Analysis of Influenza A and B Viruses Carrying Baloxavir Resistance-Associated Substitutions Serially Passaged in Human Epithelial Cells

Baloxavir marboxil (baloxavir) is an FDA-approved inhibitor of the influenza virus polymerase acidic (PA) protein. Here, we used next-generation sequencing to compare the genomic mutational profiles of IAV H1N1 and H3N2, and IBV wild type (WT) and mutants (MUT) viruses carrying baloxavir resistance-...

Full description

Bibliographic Details
Published in:	Viruses
Main Authors:	Brady T. Hickerson, Bruce K. Huang, Svetlana N. Petrovskaya, Natalia A. Ilyushina
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Subjects:	influenza baloxavir resistance polymerase substitutions viral mutation
Online Access:	https://www.mdpi.com/1999-4915/15/12/2446

Similar Items

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir
by: Vasiliy P. Mishin, et al.
Published: (2019-10-01)

Viral Fitness of Baloxavir-Resistant Recombinant Influenza B/Victoria- and B/Yamagata-like Viruses Harboring the I38T PA Change, In Vitro, Ex Vivo and in Guinea Pigs
by: Amel Saim-Mamoun, et al.
Published: (2023-04-01)

Baloxavir Marboxil: An Original New Drug against Influenza
by: François Dufrasne
Published: (2021-12-01)

Generation and Characterization of Drug-Resistant Influenza B Viruses Selected In Vitro with Baloxavir Acid
by: Amel Saim-Mamoun, et al.
Published: (2022-09-01)

Clinical efficacy and safety of baloxavir marboxil in the treatment of influenza: A systematic review and meta-analysis of randomized controlled trials
by: Yu-Chi Kuo, et al.
Published: (2021-10-01)

Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024
by: Emi Takashita, et al.
Published: (2025-05-01)

Clinical and Virologic Outcomes of Baloxavir Compared with Oseltamivir in Pediatric Patients with Influenza in Japan
by: Nobuhisa Ishiguro, et al.
Published: (2025-03-01)

In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
by: Takayuki Kuroda, et al.
Published: (2023-05-01)

Prophylactic Treatment with Baloxavir Protects Mice from Lethal Infection with Influenza A and B Viruses
by: Keita Fukao, et al.
Published: (2023-11-01)

Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China
by: Guichan Liao, et al.
Published: (2023-11-01)

Cost-Effectiveness Analysis of Influenza Treatments in Japan Using a Transmission Model: The Impact of Baloxavir and Oseltamivir Shares
by: Ataru Igarashi, et al.
Published: (2025-08-01)

Prescription factors influencing baloxavir prescription during the 2018/2019 and 2019/2020 seasons: a administrative database study in Japan
by: Naomi Fujiwara, et al.
Published: (2023-02-01)

Comparison of the efficacy and safety of baloxavir versus those of oseltamivir in pediatric patients with influenza: a meta-analysis
by: Sheng Chen, et al.
Published: (2025-10-01)

Clinical efficacy of baloxavir marboxil versus oseltamivir in kidney transplant recipients with influenza
by: Jiali Jiang, et al.
Published: (2025-07-01)

Study on the clinical efficacy and safety of baloxavir marboxil tablets in the treatment of influenza A
by: Chaochao Qiu, et al.
Published: (2024-04-01)

The Synergistic Effect of Baloxavir and Neuraminidase Inhibitors against Influenza Viruses In Vitro
by: Xiaojia Guo, et al.
Published: (2024-09-01)

Cost-Effectiveness of Baloxavir Marboxil Versus Oseltamivir or no Treatment for the Management of Influenza in the United States
by: Svenn Alexander Kommandantvold, et al.
Published: (2024-08-01)

Evaluation of Baloxavir Marboxil and Peramivir for the Treatment of High Pathogenicity Avian Influenza in Chickens
by: Augustin Twabela, et al.
Published: (2020-12-01)

Household Influenza Transmission and Healthcare Resource Utilization Among Patients Treated with Baloxavir vs Oseltamivir: A United States Outpatient Prospective Survey
by: Jennie H. Best, et al.
Published: (2024-03-01)

In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses
by: Liva Checkmahomed, et al.
Published: (2020-10-01)

Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study
by: Jiaming Li, et al.
Published: (2023-03-01)

Real-world effectiveness and safety of Baloxavir Marboxil or Oseltamivir in outpatients with uncomplicated influenza A: an ambispective, observational, multi-center study
by: Jianpeng Cai, et al.
Published: (2024-07-01)

Bunyaviral Cap-Snatching Endonuclease Activity and Inhibition with Baloxavir-like Inhibitors in the Context of Full-Length L Proteins
by: Arlo J. Loutan, et al.
Published: (2025-03-01)

Synthesis and Cap-Dependent Endonuclease Inhibition of Baloxavir Derivatives
by: Yiyun Wang, et al.
Published: (2023-06-01)

Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan
by: Nobuo Hirotsu, et al.
Published: (2023-01-01)

Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations
by: Duwe, Susanne C., et al.
Published: (2021-04-01)

Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China
by: Xilin Ge, et al.
Published: (2024-07-01)

Characterization of the In Vitro and In Vivo Efficacy of Baloxavir Marboxil against H5 Highly Pathogenic Avian Influenza Virus Infection
by: Keiichi Taniguchi, et al.
Published: (2022-01-01)

Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023–2024 flu season
by: Akihide Fujii, et al.
Published: (2025-03-01)

Innovations in the treatment and prevention of influenza in children and adolescents
by: Yu. V. Lobzin, et al.
Published: (2024-12-01)

Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses
by: Emi Takashita, et al.
Published: (2023-01-01)

Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas
by: Acocal-Juárez E, et al.
Published: (2024-09-01)

Safety evaluation of baloxavir marboxil: analysis and discussion utilizing real adverse events from the FAERS database
by: Xiaolong Lai, et al.
Published: (2025-05-01)

Validation of chromatographic method for impurity profiling of Baloxavir marboxil (Xofluza)
by: Wang Yiyun, et al.
Published: (2025-03-01)

An outbreak of influenza A(H1N1)pdm09 antigenic variants exhibiting cross-resistance to oseltamivir and peramivir in an elementary school in Japan, September 2024
by: Hideki Hasegawa
Published: (2024-12-01)

Baloxavir Marboxil Polymorphs: Investigating the Influence of Molecule Packing on the Dissolution Behavior
by: Xinbo Zhou, et al.
Published: (2022-04-01)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024-07-01)

Ultrasensitive turn-off fluorescent sensor for estimation of the new influenza antiviral prodrug baloxavir marboxil in its pharmaceutical formulation
by: Amira S. Gouda, et al.
Published: (2025-01-01)

Influenza: state-of-the-art and vaccination during COVID-19 pandemic
by: Editorial Article
Published: (2021-06-01)

Determination of baloxavir marboxil in pharmaceutical preparations and spiked human plasma using its quenching action on acetoxymercuric fluorescein reagent: Assessment of greenness and whiteness
by: Mohamed S. Nasr, et al.
Published: (2024-06-01)